Research ArticleMethodology
Three-Dimensional Dosimetry for Radioimmunotherapy Treatment Planning
George Sgouros, Stephen Chiu, Keith S. Pentlow, Linda J. Brewster, Hovanes Kalaigian, Bernard Baldwin, Farhad Daghighian, Martin C. Graham, Steven M. Larson and Radhe Mohan
Journal of Nuclear Medicine September 1993, 34 (9) 1595-1601;
George Sgouros
Stephen Chiu
Keith S. Pentlow
Linda J. Brewster
Hovanes Kalaigian
Bernard Baldwin
Farhad Daghighian
Martin C. Graham
Steven M. Larson


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Three-Dimensional Dosimetry for Radioimmunotherapy Treatment Planning
George Sgouros, Stephen Chiu, Keith S. Pentlow, Linda J. Brewster, Hovanes Kalaigian, Bernard Baldwin, Farhad Daghighian, Martin C. Graham, Steven M. Larson, Radhe Mohan
Journal of Nuclear Medicine Sep 1993, 34 (9) 1595-1601;
Jump to section
Related Articles
- No related articles found.
Cited By...
- MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
- Metabolic Tumor Volume in Lymphoma: Hype or Hope?
- MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
- RADAR Realistic Animal Model Series for Dose Assessment
- Voxel-Based Mouse and Rat Models for Internal Dose Calculations
- Dosimetry of Internal Emitters
- Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response
- Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
- A 3-Dimensional Absorbed Dose Calculation Method Based on Quantitative SPECT for Radionuclide Therapy: Evaluation for 131I Using Monte Carlo Simulation
- Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131I-MIBG